

PA000IPRI02

**Pemetrexed I.P.**  
**ALIMTA® 500mg**  
**ALIMTA® 100mg**  
**Powder for Concentrate for Solution for Infusion**

**Pemetrexed I.P.**

**ALIMTA® 500mg**  
**ALIMTA® 100mg**

**Powder for Concentrate for Solution for Infusion**

**NAME OF THE MEDICINAL PRODUCT**

ALIMTA® 500 mg powder for concentrate for solution for infusion.

ALIMTA® 100 mg powder for concentrate for solution for infusion.

**QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 500 mg vial contains 500 mg of Pemetrexed I.P. (Formulated with Pemetrexed Disodium Heptahydrate I.P.), 500 mg Mannitol I.P. as bulking agent, Hydrochloric Acid solution I.P. (10 %) q.s. and/or Sodium Hydroxide solution I.P. (10 %) q.s. may have been added for pH adjustment.

Each 100 mg vial contains 100 mg of Pemetrexed I.P. (Formulated with Pemetrexed Disodium Heptahydrate I.P.), 106.4 mg Mannitol I.P. as bulking agent, Hydrochloric Acid solution I.P. (10 %) q.s. and/or Sodium Hydroxide solution I.P. (10 %) q.s. may have been added for pH adjustment.

**PHARMACEUTICAL FORM**

Powder for concentrate for solution for infusion.

A white to either light yellow or green-yellow lyophilised powder.

**CLINICAL PARTICULARS**

**Therapeutic indications**

Malignant Pleural Mesothelioma:

ALIMTA® in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma (see section *"Pharmacodynamic properties"*).

Non-small cell lung cancer:

ALIMTA® in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section *"Pharmacodynamic properties"*).

ALIMTA® is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section *"Pharmacodynamic properties"*).

ALIMTA® is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section *"Pharmacodynamic properties"*).

**Posology and method of administration**

**Posology:**

ALIMTA® must only be administered under the supervision of a physician qualified in the use of anti-cancer chemotherapy.

The ALIMTA® solution must be prepared according to the instructions provided in section Instructions for use, handling and disposal.

**ALIMTA® in combination with cisplatin:**

The recommended dose of ALIMTA® is 500 mg/m<sup>2</sup> of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m<sup>2</sup> BSA infused over two hours approximately 30 minutes after completion of the pemetrexed infusion on the first day of each 21-day cycle. Patients must receive adequate anti-emetic treatment and appropriate hydration prior to and/or after receiving cisplatin (See also cisplatin package insert for specific dosing advice).

**ALIMTA® as single agent:**

In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of ALIMTA® is 500 mg/m<sup>2</sup> BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.

**Premedication regimen:**

To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration.

The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day (see section *"Special warnings and precautions for use"*).

To reduce toxicity, patients treated with pemetrexed must also receive vitamin supplementation (see section *"Special warnings and precautions for use"*). Patients must take oral folic acid or a multivitamin containing folic acid (350 to 1000 micrograms) on a daily basis. At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed. Patients must also receive an intramuscular injection of vitamin B<sub>12</sub> (1000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles thereafter. Subsequent vitamin B<sub>12</sub> injections may be given on the same day as pemetrexed.

**Monitoring:**

Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential white cell count (WCC) and platelet count. Prior to each chemotherapy administration blood chemistry tests should be collected to evaluate renal and hepatic function. Before the start of any cycle of chemotherapy, patients are required to have the following: Absolute Neutrophil Count (ANC) should be ≥ 1500 cells/mm<sup>3</sup> and platelets should be ≥ 100,000 cells/mm<sup>3</sup>.

Creatinine clearance should be ≥ 45 ml/min.

The total bilirubin should be ≤ 1.5 times upper limit of normal. Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be ≤ 3 times upper limit of normal. Alkaline phosphatase, AST and ALT ≤ 5 times upper limit of normal is acceptable if liver has tumour involvement.

**Dose Adjustments:**

Dose adjustments at the start of a subsequent cycle should be based on nadir haematologic counts or maximum non-haematologic toxicity from the preceding cycle of therapy. Treatment may be delayed to allow sufficient time for recovery. Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for ALIMTA® used as a single agent or in combination with cisplatin.

Table 1 - Dose Modification Table for ALIMTA® (as single agent or in combination) AND Cisplatin Haematologic Toxicities		
Nadir ANC < 500 /mm <sup>3</sup> and nadir platelets ≥ 50,000 /mm <sup>3</sup>	75 % of previous dose (both ALIMTA® and cisplatin).	
Nadir platelets <50,000 /mm <sup>3</sup> regardless of nadir ANC	75 % of previous dose (both ALIMTA® and cisplatin).	
Nadir platelets <50,000/mm <sup>3</sup> with bleeding <sup>a</sup> , regardless of nadir ANC.	50% of previous dose (both ALIMTA® and cisplatin).	

<sup>a</sup> These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding

If patients develop non-haematologic toxicities ≥ Grade 3 (excluding neurotoxicity), ALIMTA® should be withheld until resolution to less than or equal to the patient's pre-therapy value. Treatment should be resumed according to the guidelines in Table 2.

Table 2 - Dose Modification Table for ALIMTA® (as single agent or in combination) and Cisplatin– Non-haematologic Toxicities <sup>a, b</sup>		
	Dose of ALIMTA® (mg/m <sup>2</sup> )	Dose for cisplatin (mg/m <sup>2</sup> )
Any Grade 3 or 4 toxicities except mucositis	75 % of previous dose	75 % of previous dose
Any diarrhoea requiring hospitalisation (irrespective of grade) or grade 3 or 4 diarrhoea.	75 % of previous dose	75 % of previous dose
Grade 3 or 4 mucositis	50 % of previous dose	100 % of previous dose

<sup>a</sup> National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998); <sup>b</sup> Excluding neurotoxicity

In the event of neurotoxicity, the recommended dose adjustment for ALIMTA® and cisplatin is documented in Table 3. Patients should discontinue therapy if Grade 3 or 4 neurotoxicity is observed.

Table 3 - Dose Modification for ALIMTA® (as single agent or in combination) and Cisplatin – Neurotoxicity		
CTC <sup>a</sup> Grade	Dose of ALIMTA® (mg/m <sup>2</sup> )	Dose for cisplatin (mg/m <sup>2</sup> )
0 – 1	100 % of previous dose	100 % of previous dose
2	100 % of previous dose	50 % of previous dose

<sup>a</sup> National Cancer Institute Common Toxicity Criteria (CTC v 2.0; NCI 1998)

Treatment with ALIMTA® should be discontinued if a patient experiences any haematologic or non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed.

**Elderly:** In clinical studies, there has been no indication that patients 65 years of age or older are at increased risk of adverse events compared to patients younger than 65 years old. No dose reductions other than those recommended for all patients are necessary.

**Paediatric population:** There is no relevant use of ALIMTA® in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer.

**Patients with Renal Impairment:** (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DTPA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion. In clinical studies, patients with creatinine clearance of ≥ 45 ml/min required no dose adjustments other than those recommended for all patients. There are insufficient data on the use of pemetrexed in patients with creatinine clearance below 45 ml/min; therefore the use of pemetrexed is not recommended (see section *"special warnings and precautions for use"*).

**Patients with Hepatic Impairment:** No relationships between AST (SGOT), ALT (SGPT), or total bilirubin and pemetrexed pharmacokinetics were identified. However patients with hepatic impairment such as bilirubin > 1.5 times the upper limit of normal and/or aminotransferase > 3.0 times the upper limit of normal (hepatic metastases absent) or > 5.0 times the upper limit of normal (hepatic metastases present) have not been specifically studied.

**Method of administration:**

For *precautions to be taken before handling or administering* ALIMTA®, see section *"Special precautions for disposal and other handling"*.

ALIMTA® should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. For instructions on reconstitution and dilution of ALIMTA® before administration, see section *"Special precautions for disposal and other handling"*.

**Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section *"List of excipients"*.

Breast-feeding must be discontinued during pemetrexed therapy (see section *"Pregnancy and lactation"*).

Concomitant yellow fever vaccine (see section *"Interaction with other medicinal products and other forms of interaction"*).

**Special warnings and precautions for use**

Pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia and anaemia (or pancytopenia) (see section Undesirable effects).

Myelosuppression is usually the dose-limiting toxicity. Patients should be monitored for myelosuppression during therapy and pemetrexed should not be given to patients until absolute neutrophil count (ANC) returns to ≥ 1500 cells/mm<sup>3</sup> and platelet count returns to ≥ 100,000 cells/mm<sup>3</sup>. Dose reductions for subsequent cycles are based on nadir ANC, platelet count and maximum non-haematologic toxicity seen from the previous cycle (see section *"Posology and method of administration"*).

Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities such as neutropenia, febrile neutropenia and infection with Grade 3/4 neutropenia were reported when pre-treatment with folic acid and vitamin B<sub>12</sub> was administered. Therefore, all patients treated with pemetrexed must be instructed to take folic acid and vitamin B<sub>12</sub> as a prophylactic measure to reduce treatment-related toxicity (see section *"Posology and method of administration"*).

Skin reactions have been reported in patients not pre-treated with a corticosteroid. Pre-treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions (see section *"Posology and method of administration"*).

An insufficient number of patients has been studied with creatinine clearance of below 45 ml/min. Therefore, the use of pemetrexed in patients with creatinine clearance of < 45 ml/min is not recommended (see section *"Posology and method of administration"*).

Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs) as ibuprofen, and aspirin (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section *"Interaction with other medicinal products and other forms of interaction"*).

In patients with mild to moderate renal insufficiency eligible for pemetrexed therapy NSAIDs with long elimination half-lives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section *"Interaction with other medicinal products and other forms of interaction"*).

Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in association with other chemotherapeutic agents. Many of the patients in whom these occurred had underlying risk factors for the development of renal events including dehydration or pre-existing hypertension or diabetes.

The effect of third space fluid, such as pleural effusion or ascites, on pemetrexed is not fully defined. A phase 2 study of pemetrexed in 31 solid tumor patients with stable third space fluid demonstrated no difference in pemetrexed dose-normalized plasma concentrations or clearance compared to patients without third space fluid collections. Thus, drainage of third space fluid collection prior to pemetrexed treatment should be considered, but may not be necessary.

Due to the gastrointestinal toxicity of pemetrexed given in combination with cisplatin, severe dehydration has been observed. Therefore, patients should receive adequate antiemetic treatment and appropriate hydration prior to and/or after receiving treatment.

Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had pre-existing cardiovascular risk factors (see section *"Undesirable effects"*).

Immunodepressed status is common in cancer patients. As a result, concomitant use of live attenuated vaccines is not recommended (see section *"Interaction with other medicinal products and other forms of interaction"*).

Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter.

Contraceptive measures or abstinence are recommended. Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.

Women of childbearing potential must use effective contraception during treatment with pemetrexed (see section *"Pregnancy and lactation"*).

Cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy. Particular attention should be paid to these patients and caution exercised with use of other radiosensitising agents.

Cases of radiation recall have been reported in patients who received radiotherapy weeks or years previously.

**Interaction with other medicinal products and other forms of interaction**

Pemetrexed is mainly eliminated unchanged renally by tubular secretion and to a lesser extent by glomerular filtration. Concomitant administration of nephrotoxic drugs (e.g. aminoglycoside, loop diuretics, platinum compounds, cyclosporin) could potentially result in delayed clearance of pemetrexed. This combination should be used with caution. If necessary, creatinine clearance should be closely monitored.

Concomitant administration of substances that are also tubularly secreted (e.g. probenecid, penicillin) could potentially result in delayed clearance of pemetrexed. Caution should be made when these drugs are combined with pemetrexed. If necessary, creatinine clearance should be closely monitored.

In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen > 1600 mg/day) and aspirin at higher dosage (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events. Therefore, caution should be made when administering higher doses of NSAIDs or aspirin at higher dosage, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).

In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dosage should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section *"Special warnings and precautions for use"*).

In the absence of data regarding potential interaction with NSAIDs having longer half-lives as piroxicam or rofecoxib, the concomitant administration with pemetrexed in patients with mild to moderate renal insufficiency should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section *"Special warnings and precautions for use"*). If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression and gastrointestinal toxicity.

Pemetrexed undergoes limited hepatic metabolism. Results from *in vitro* studies with human liver microsomes indicated that pemetrexed would not be predicted to cause clinically significant inhibition of the metabolic clearance of drugs metabolised by CYP3A, CYP2D6, CYP2C9, and CYP1A2.

Interactions common to all cytotoxics:

Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent. The high intra-individual variability of the coagulation status during diseases and the possibility of interaction between oral anticoagulants and anticancer chemotherapy require increased frequency of INR (International Normalised Ratio) monitoring, if it is decided to treat the patient with oral anticoagulants.

Concomitant use contraindicated: Yellow fever vaccine: risk of fatal generalised vaccinal disease (see section *Contraindications*).

Concomitant use not recommended: Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease. The risk is increased in subjects who are already immunosuppressed by their underlying disease. Use an inactivated vaccine where it exists (poliomyelitis) (see section *Special warnings and precautions for use*).

**Fertility, pregnancy and lactation**

Contraception in males and females:

Women of childbearing potential must use effective contraception during treatment with pemetrexed. Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended.

**Pregnancy:**

There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other anti-metabolites, is suspected to cause serious birth defects when administered during pregnancy. Animal studies have shown reproductive toxicity (see section *Preclinical safety data*). Pemetrexed should not be used during pregnancy unless clearly necessary, after a careful consideration of the needs of the mother and the risk for the foetus (see section *Special warnings and precautions for use*).

**Breastfeeding:**

It is not known whether pemetrexed is excreted in human milk and adverse reactions on the suckling child cannot be excluded. Breast-feeding must be discontinued during pemetrexed therapy (see section *Contraindications*).

**Fertility:**

Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.

**Effects on ability to drive and use machines**

No studies on the effects on the ability to drive and use machines have been performed. However, it has been reported that pemetrexed may cause fatigue. Therefore patients should be cautioned against driving or operating machines if this event occurs.

**Undesirable effects**

Summary of the safety profile

The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis.

The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin. In both treatment arms, these chemonaive patients were fully supplemented with folic acid and vitamin B<sub>12</sub>.

**Adverse reactions**

Frequency estimate: Very common (≥1/10), Common (≥1/100 and <1/10), Uncommon (≥1/1000 and <1/100), Rare (≥1/10,000 and <1/1000), Very Rare (<1/10,000) and Not known (cannot be estimated from available data-spontaneous reports).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ Class	Frequency	Event*	Pemetrexed/cisplatin		Cisplatin	
			(N = 168)		(N = 163)	
			All Grades Toxicity (%)	Grade 3 - 4 Toxicity (%)	All Grades Toxicity (%)	Grade 3 - 4 Toxicity (%)
Blood and Lymphatic System Disorders	Very Common	Neutrophils/Granulocytes Decreased	56.0	23.2	13.5	3.1
		Leukocytes Decreased	53.0	14.9	16.6	0.6
		Haemoglobin Decreased	26.2	4.2	10.4	0.0
		Platelets Decreased	23.2	5.4	8.6	0.0
Eye Disorders	Common	Conjunctivitis	5.4	0.0	0.6	0.0
Gastrointestinal Disorders	Very Common	Diarrhoea	16.7	3.6	8.0	0.0
		Vomiting	56.5	10.7	49.7	4.3
		Stomatitis/Pharyngitis	23.2	3.0	6.1	0.0
		Nausea	82.1	11.9	76.7	5.5
		Anorexia	20.2	1.2	14.1	0.6
		Constipation	11.9	0.6	7.4	0.6
		Dyspepsia	5.4	0.6	0.6	0.0
General Disorders and administrative site condition	Very Common	Fatigue	47.6	10.1	42.3	9.2
Metabolism and Nutrition Disorders	Common	Dehydration	6.5	4.2	0.6	0.6
Nervous System Disorders	Very Common	Neuropathy-Sensory	10.1	0.0	9.8	0.6
	Common	Taste disturbance	7.7	0.0***	6.1	0.0**
Renal and Urinary Disorders	Very Common	Creatinine Elevation	10.7	0.6	9.8	1.2
		Creatinine clearance decreased**	16.1	0.6	17.8	1.8
Skin and Subcutaneous tissue Disorders	Very Common	Rash	16.1	0.6	4.9	0.0
		Alopecia	11.3	0.0***	5.5	0.0***

Refer to National Cancer Institute CTC version 2 for each grade of toxicity except the term *"creatinine clearance decreased"*

\*\*\* which is derived from the term *"renal/genitourinary other"*.

\*\*According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.

For the purpose of this table a cut off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.

Clinically relevant CTC toxicities that were reported in - ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropaenia, increased AST, ALT, and GGT, urticaria and chest pain.

Clinically relevant CTC toxicities that were reported in < 1 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include arrhythmia and motor neuropathy.

The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and vitamin B<sub>12</sub> supplementation and 276 patients randomly assigned to receive single agent docetaxel. All patients were diagnosed with locally advanced or metastatic non-small cell lung cancer and received prior chemotherapy.

System organ class	Frequency	Event*	Pemetrexed N = 265		Docetaxel N = 276	
			All grades toxicity (%)	Grade 3 – 4 toxicity (%)	All Grades toxicity (%)	Grade 3 – 4 toxicity (%)
Blood and lymphatic system disorders	Very Common	Neutrophils/Granulocytes decreased	10.9	5.3	45.3	40.2
		Leukocytes Decreased	12.1	4.2	34.1	27.2
		Haemoglobin Decreased	19.2	4.2	22.1	4.3
	Common	Platelets decreased	8.3	1.9	1.1	0.4
Gastrointestinal Disorders	Very Common	Diarrhoea	12.8	0.4	24.3	2.5
		Vomiting	16.2	1.5	12.0	1.1
		Stomatitis/Pharyngitis	14.7	1.1	17.4	1.1
		Nausea	30.9	2.6	16.7	1.8
		Anorexia	21.9	1.9	23.9	2.5
	Common	Constipation	5.7	0.0	4.0	0.0
Hepatobiliary Disorders	Common	SGPT (ALT) Elevation	7.9	1.9	1.4	0.0
		SGOT (AST) Elevation	6.8	1.1	0.7	0.0
Skin and subcutaneous tissue disorders	Very Common	Rash/desquamation	14.0	0.0	6.2	0.0
	Common	Pruritus	6.8	0.4	1.8	0.0
		Alopecia	6.4	0.4**	37.7	2.2**
General disorders and administration site conditions	Very Common	Fatigue	34.0	5.3	35.9	5.4
	Common	Fever	8.3	0.0	7.6	0.0



System organ class	Frequency*	Event**	Pemetrexed*** (N =800)		Placebo*** (N =402)	
			All grades toxicity (%)	Grade 3 - 4 toxicity (%)	All grades toxicity (%)	Grade 3 - 4 toxicity (%)
Blood and lymphatic system disorders	Very common	Hemoglobin decreased	18.0	4.5	5.2	0.5
	Common	Leukocytes decreased	5.8	1.9	0.7	0.2
		Neutrophils decreased	8.4	4.4	0.2	0.0
Nervous system disorders	Common	Neuropathy-sensory	7.4	0.6	5.0	0.2
Gastrointestinal disorders	Very common	Nausea	17.3	0.8	4.0	0.2
		Anorexia	12.8	1.1	3.2	0.0
	Common	Vomiting	8.4	0.3	1.5	0.0
		Mucositis/stomatitis	6.8	0.8	1.7	0.0
Hepatobiliary disorders	Common	ALT (SGPT) elevation	6.5	0.1	2.2	0.0
		AST (SGOT) elevation	5.9	0.0	1.7	0.0
Skin and subcutaneous tissue disorders	Common	Rash/desquamation	8.1	0.1	3.7	0.0
General disorders and administration site disorders	Very common	Fatigue	24.1	5.3	10.9	0.7
	Common	Pain	7.6	0.9	4.5	0.0
		Edema	5.6	0.0	1.5	0.0
Renal Disorders	Common	Renal disorders****	7.6	0.9	1.7	0.0

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Events; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.  
\* Definition of frequency terms: Very common - > 10%; Common - > 5% and < 10%. For the purpose of this table, a cutoff of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.  
\*\* Refer to NCI CTCAE Criteria (Version 3.0, NCI 2003) for each grade of toxicity. The reporting rates shown are according to CTCAE version 3.0.  
\*\*\* Integrated adverse reactions table combines the results of the JMEN pemetrexed maintenance (N=663) and PARAMOUNT continuation pemetrexed maintenance (N=539) studies.  
\*\*\*\* Combined term includes increased serum/blood creatinine, decreased glomerular filtration rate, renal failure and renal/genitourinary- other.

Clinically relevant CTC toxicity of any grade that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to pemetrexed include: febrile neutropenia, infection, decreased platelets, diarrhoea, constipation, alopecia, pruritus/itching, fever (in the absence of neutropenia), ocular surface disease (including conjunctivitis), increased lacrimation, dizziness and motor neuropathy.

Clinically relevant CTC toxicity that was reported in <1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.

Safety was assessed for patients who were randomised to receive pemetrexed (N=800). The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N=519), and compared to patients who received > 6 cycles of pemetrexed (N=281). Increases in adverse reactions (all grades) were observed with longer exposure. A significant increase in the incidence of possibly study-drug-related Grade 3/4 neuropenia was observed with longer exposure to pemetrexed (≤6 cycles: 3.3%, > 6cycles: 6.4%; p=0.046). No statistically significant differences in any other individual Grade 3/4/5 adverse reactions were seen with longer exposure.

Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischaemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent. Most of the patients in whom these events have been observed had pre-existing cardiovascular risk factors.

Rare cases of hepatitis, potentially serious, have been reported during clinical studies with pemetrexed.

Pancytopenia has been uncommonly reported during clinical trials with pemetrexed.

In clinical trials, cases of colitis (including intestinal and rectal bleeding, sometimes fatal, intestinal perforation, intestinal necrosis and typhilitis) have been reported uncommonly in patients treated with pemetrexed.

In clinical trials, cases of interstitial pneumonitis with respiratory insufficiency, sometimes fatal, have been reported uncommonly in patients treated with pemetrexed.

Uncommon cases of oedema have been reported in patients treated with pemetrexed.

Oesophagitis/radiation oesophagitis has been uncommonly reported during clinical trials with pemetrexed.

Sepsis, sometimes fatal, has been commonly reported during clinical trials with pemetrexed.

During post marketing surveillance, the following adverse reactions have been reported in patients treated with pemetrexed:

Uncommon cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section *Special warnings and precautions for use*).

Uncommon cases of radiation pneumonitis have been reported in patients treated with radiation either prior, during or subsequent to their pemetrexed therapy (see section *Special warnings and precautions for use*).

Rare cases of bullous conditions have been reported including Stevens-Johnson syndrome and Toxic epidermal necrolysis which in some cases were fatal.

Rare cases of radiation recall have been reported in patients who have received radiotherapy previously (see section *Special warnings and precautions for use*).

Uncommon cases of peripheral ischaemia leading sometimes to extremity necrosis has been reported.

Rarely, immune-mediated haemolytic anaemia has been reported in patients treated with pemetrexed.

Rare cases of anaphylactic shock have been reported.

#### Overdose

Reported symptoms of overdose include neutropoenia, anaemia, thrombocytopenia, mucositis, sensory polyneuropathy and rash. Anticipated complications of overdose include bone marrow suppression as manifested by neutropoenia, thrombocytopenia and anaemia. In addition, infection with or without fever, diarrhoea, and/or mucositis may be seen. In the event of suspected overdose, patients should be monitored with blood counts and should receive supportive therapy as necessary. The use of calcium folinate / folic acid in the management of pemetrexed overdose should be considered.

#### PHARMACOLOGICAL PROPERTIES

##### Pharmacodynamic properties

Pharmacotherapeutic group: Folic acid analogues, ATC code: L01BA04

ALIMTA® (pemetrexed) is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.

*In vitro* studies have shown that pemetrexed behaves as a multitargeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycylamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the *de novo* biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme polyglutamate synthetase. The polyglutamate forms are retained in cells and are even more potent inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumour cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

##### Clinical efficacy:

##### Mesothelioma:

EMPHACIS, a multicentre, randomised, single-blind phase 3 study of ALIMTA® plus cisplatin versus cisplatin in chemo-naïve patients with malignant pleural mesothelioma, has shown that patients treated with ALIMTA® and cisplatin had a clinically meaningful 2.8-month median survival advantage over patients receiving cisplatin alone.

During the study, low-dose folic acid and vitamin B<sub>12</sub> supplementation was introduced to patients' therapy to reduce toxicity. The primary analysis of this study was performed on the population of all patients randomly assigned to a treatment arm who received study drug (randomised and treated). A subgroup analysis was performed on patients who received folic acid and vitamin B<sub>12</sub> supplementation during the entire course of study therapy (fully supplemented). The results of these analyses of efficacy are summarised in the table below:

#### Efficacy of ALIMTA® plus Cisplatin vs. Cisplatin in Malignant Pleural Mesothelioma

Efficacy parameter	Randomized and treated Patients		Fully supplemented patients	
	ALIMTA®/ cisplatin (N = 226)	Cisplatin (N = 222)	ALIMTA®/ cisplatin (N = 168)	Cisplatin (N = 163)
Median overall survival (months) (95 % CI)	12.1 (10.0 - 14.4)	9.3 (7.8 - 10.7)	13.3 (11.4 - 14.9)	10.0 (8.4 - 11.9)
Log Rank p-value*	0.020		0.051	
Median time to tumour progression (months) (95 % CI)	5.7 (4.9 - 6.5)	3.9 (2.8 - 4.4)	6.1 (5.3 - 7.0)	3.9 (2.8 - 4.5)
Log Rank p-value*	0.001		0.008	
Time to treatment failure (months) (95 % CI)	4.5 (3.9 - 4.9)	2.7 (2.1 - 2.9)	4.7 (4.3 - 5.6)	2.7 (2.2 - 3.1)
Log Rank p-value*	0.001		0.001	
Overall response rate** (95 % CI)	41.3 % (34.8 - 48.1)	16.7 % (12.0 - 22.2)	45.5 % (37.8 - 53.4)	19.6 % (13.8 - 26.6)
Fisher's exact p-value*	< 0.001		< 0.001	

Abbreviation: CI = confidence interval

\* p-value refers to comparison between arms.

\*\* In the ALIMTA®/cisplatin arm, randomised and treated (N = 225) and fully supplemented (N = 167)

A statistically significant improvement of the clinically relevant symptoms (pain and dyspnoea) associated with malignant pleural mesothelioma in the ALIMTA®/cisplatin arm (212 patients) versus the cisplatin arm alone (218 patients) was demonstrated using the Lung Cancer Symptom Scale. Statistically significant differences in pulmonary function tests were also observed. The separation between the treatment arms was achieved by improvement in lung function in the ALIMTA®/cisplatin arm and deterioration of lung function over time in the control arm.

There are limited data in patients with malignant pleural mesothelioma treated with ALIMTA® alone. ALIMTA® at a dose of 500 mg/m<sup>2</sup> was studied as a single-agent in 64 chemo-naïve patients with malignant pleural mesothelioma. The overall response rate was 14.1 %.

#### NSCLC, Second-Line Treatment:

A multicentre, randomised, open label phase 3 study of ALIMTA® versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with ALIMTA® (Intent To Treat population n = 283) and 7.9 months for patients treated with docetaxel (ITT n = 288). Prior chemotherapy did not include ALIMTA®. An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of ALIMTA® versus docetaxel for other than predominantly squamous histologies (n=399, 9.3 versus 8.0 months, adjusted HR = 0.78; 95% CI=0.61-1.00, p=0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n=172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI=1.08-2.26, p=0.018). There were no clinically relevant differences observed for the safety profile of ALIMTA® within the histology subgroups.

Limited clinical data from a separate randomised, Phase 3, controlled trial, suggest that efficacy data (overall survival, progression free survival) for pemetrexed are similar between patients previously pre treated with docetaxel (n=41) and patients who did not receive previous docetaxel treatment (n=540).

#### Efficacy of ALIMTA® vs docetaxel in NSCLC - ITT Population

Survival Time (months)	ALIMTA® (n = 283)	Docetaxel (n = 288)
	8.3 (7.0 - 9.4)	7.9 (6.3 - 9.2)
	0.99 (.82 - 1.20)	
	.226	
Progression free survival (months)	(n = 283)	(n = 288)
■ Median	2.9	2.9
■ HR (95 % CI)	0.97 (.82 – 1.16)	
Time to treatment failure (TTTF – months)	(n = 283)	(n = 288)
■ Median	2.3	2.1
■ HR (95 % CI)	0.84 (.71 - .977)	
Response (n: qualified for response)	(n = 264)	(n = 274)
■ Response rate (%) (95 % CI)	9.1 (5.9 - 13.2)	8.8 (5.7 - 12.8)
■ Stable disease (%)	45.8	46.4

Abbreviations: CI = confidence interval; HR = hazard ratio; ITT = intent to treat; n = total population size.

#### NSCLC, First-Line Treatment:

A multicentre, randomised, open-label, Phase 3 study of ALIMTA® plus cisplatin versus gemcitabine plus cisplatin in chemo-naïve patients with locally advanced or metastatic (Stage IIb or IV) non-small cell lung cancer (NSCLC) showed that ALIMTA® plus cisplatin (Intent-To-Treat [ITT] population n = 862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT n = 863) in overall survival (adjusted hazard ratio 0.94; 95% CI 0.84-1.05). All patients included in this study had an ECOG performance status 0 or 1.

The primary efficacy analysis was based on the ITT population. Sensitivity analyses of main efficacy endpoints were also assessed on the Protocol Qualified (PQ) population. The efficacy analyses using PQ population are consistent with the analyses for the ITT population and support the non-inferiority of AC versus GC.

Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for ALIMTA® plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI 0.94-1.15), and overall response rate was 30.6% (95% CI 27.3- 33.9) for ALIMTA® plus cisplatin versus 28.2% (95% CI 25.0-31.4) for gemcitabine plus cisplatin. PFS data were partially confirmed by an independent review (400/1725 patients were randomly selected for review).

The analysis of the impact of NSCLC histology on overall survival demonstrated clinically relevant differences in survival according to histology, see table below.


#### Efficacy of ALIMTA® + Cisplatin vs. Gemcitabine + Cisplatin in First-Line Non-Small Cell Lung Cancer – ITT Population and Histology Subgroups.

ITT Population and Histology Subgroups	Median Overall Survival in Months (95% CI)				Adjusted Hazard Ratio (HR) (95% CI)	Superiority p-value
	ALIMTA® + Cisplatin		Gemcitabine + Cisplatin			
ITT Population (N = 1725)	10.3 (9.8 - 11.2)	N=862	10.3 (9.6 - 10.9)	N=863	0.94 <sup>a</sup> (0.84 - 1.05)	0.259
Adenocarcinoma (N=847)	12.6 (10.7 - 13.6)	N=436	10.9 (10.2 - 11.9)	N=411	0.84 (0.71-0.99)	0.033
Large Cell (N=153)	10.4 (8.6 - 14.1)	N=76	6.7 (5.5 - 9.0)	N=77	0.67 (0.48-0.96)	0.027
Other (N=252)	8.6 (6.8 - 10.2)	N=106	9.2 (8.1 - 10.6)	N=146	1.08 (0.81-1.45)	0.586
Squamous Cell (N=473)	9.4 (8.4 - 10.2)	N=244	10.8 (9.5 - 12.1)	N=229	1.23 (1.00-1.51)	0.050

Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size.

<sup>a</sup> Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17845 noninferiority margin (p <0.001).

#### Kaplan Meier Plots of Overall Survival by Histology



There were no clinically relevant differences observed for the safety profile of ALIMTA® plus cisplatin within the histology subgroups.

Patients treated with ALIMTA® and cisplatin required fewer transfusions (16.4% versus 28.9%, p<0.001), red blood cell transfusions (16.1% versus 27.3%, p<0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002). Patients also required lower administration of erythropoietin/darbepoietin (10.4% versus 18.1%, p<0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p=0.004), and iron preparations (4.3% versus 7.0%, p=0.021).

#### NSCLC, Maintenance Treatment:

A multicentre, randomised, double-blind, placebo-controlled Phase 3 study (JMEN), compared the efficacy and safety of maintenance treatment with ALIMTA® plus best supportive care (BSC) (n = 441) with that of placebo plus BSC (n= 222) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) who did not progress after 4 cycles of first line doublet therapy containing Cisplatin or Carboplatin in combination with Gemcitabine, Paclitaxel, or Docetaxel. First line doublet therapy containing ALIMTA® was not included. All patients included in this study had an ECOG performance status 0 or 1. Patients received maintenance treatment until disease progression. Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy. Patients received a median of 5 cycles of maintenance treatment with ALIMTA® and 3.5 cycles of placebo. A total of 213 patients (48.3%) completed ≥ 6 cycles and a total of 103 patients (23.4%) completed ≥ 10 cycles of treatment with ALIMTA®.


The study met its primary endpoint and showed a statistically significant improvement in PFS in the ALIMTA® arm over the placebo arm (n = 581, independently reviewed population; median of 4.0 months and 2.0 months, respectively) (hazard ratio = 0.60, 95% CI: 0.49-0.73, p < 0.00001). The independent review of patient scans confirmed the findings of the investigator assessment of PFS. The median OS for the overall population (n = 663) was 13.4 months for the ALIMTA® arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI: 0.65 to 0.95; p = 0.01192).

Consistent with other ALIMTA® studies, a difference in efficacy according to NSCLC histology was observed in JMEN. For patients with NSCLC other than predominantly squamous cell histology (n= 430, independently reviewed population) median PFS was 4.4 months for the ALIMTA® arm and 1.8 months for the placebo arm, hazard ratio = 0.47, 95% CI: 0.37-0.60, p= 0.00001. The median OS for patients with NSCLC other than predominantly squamous cell histology (n = 481) was 15.5 months for the ALIMTA® arm and 10.3 months for the placebo arm (hazard ratio = 0.70, 95% CI: 0.56-0.88, p=0.002). Including the induction phase the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the ALIMTA® arm and 13.6 months for the placebo arm (hazard ratio =0.71, 95% CI: 0.56-0.88, p=0.002).

The PFS and OS results in patients with squamous cell histology suggested no advantage for ALIMTA® over placebo.

There were no clinically relevant differences observed for the safety profile of ALIMTA® within the histology subgroups.

#### Kaplan Meier Plots of Progression-Free Survival (PFS) and Overall Survival ALIMTA® versus Placebo in Patients with NSCLC other than Predominantly Squamous Cell Histology




#### PARAMOUNT

A multicentre, randomised, double-blind, placebo-controlled Phase 3 study (PARAMOUNT), compared the efficacy and safety of continuation maintenance treatment with ALIMTA® plus BSC (n = 359) with that of placebo plus BSC (n = 180) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than predominantly squamous cell histology who did not progress after 4 cycles of first line doublet therapy of ALIMTA® in combination with cisplatin. Of the 939 patients treated with ALIMTA® plus cisplatin induction, 539 patients were randomised to maintenance treatment with pemetrexed or placebo. Of the randomised patients, 44.9% had a complete/partial response and 51.9% had a response of stable disease to ALIMTA® plus cisplatin induction. Patients randomised to maintenance treatment were required to have an ECOG performance status 0 or 1. The median time from the start of ALIMTA® plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm. Randomised patients received maintenance treatment until disease progression. Efficacy and safety were measured from the time of randomisation after completion of first line (induction) therapy. Patients received a median of 4 cycles of maintenance treatment with ALIMTA® and 4 cycles of placebo. A total of 169 patients (47.1%) completed ≥ 6 cycles maintenance treatment with ALIMTA®, representing at least 10 total cycles of ALIMTA®.

The study met its primary endpoint and showed a statistically significant improvement in PFS in the ALIMTA® arm over the placebo arm (n = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95% CI = 0.51-0.81, p = 0.0002). The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomized patients, as measured from the start of ALIMTA® plus cisplatin first line induction treatment, the median investigator-assessed PFS was 6.9 months for the ALIMTA® arm and 5.6 months for the placebo arm (hazard ratio = 0.59 95% CI = 0.47-0.74).

Following ALIMTA® plus cisplatin induction (4 cycles), treatment with ALIMTA® was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95%CI=0.64-0.96, p=0.0195). At the time of this final survival analysis, 28.7% of patients were alive or best to follow up on the ALIMTA® arm versus 21.7% on the placebo arm. The relative treatment effect of ALIMTA® was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses. The 1 year and 2 year survival rates for patients on ALIMTA® were 58% and 32% respectively, compared to 45% and 21% for patients on placebo. From the start of ALIMTA® plus cisplatin first line induction treatment, the median OS of patients was 16.9 months for the ALIMTA® arm and 14.0 months for the placebo arm (hazard ratio= 0.78, 95% CI= 0.64-0.96). The percentage of patients that received post study treatment was 64.3% for ALIMTA® and 71.7% for placebo.

#### PARAMOUNT:Kaplan Meier plot of progression-free survival (PFS) and Overall Survival (OS) for continuation ALIMTA maintenance versus placebo in patients with NSCLC other than predominantly squamous cell histology (measured from randomisation)



The ALIMTA maintenance safety profiles from the two studies JMEN and PARAMOUNT were similar.

#### Pharmacokinetic properties

The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838 mg/m<sup>2</sup> infused over a 10-minute period. Pemetrexed has a steady-state volume of distribution of 9 l/m<sup>2</sup>. *In vitro* studies indicate that pemetrexed is approximately 81 % bound to plasma proteins. Binding was not notably affected by varying degrees of renal impairment. Pemetrexed undergoes limited hepatic metabolism. Pemetrexed is primarily eliminated in the urine, with 70 % to 90 % of the administered dose being recovered unchanged in urine within the first 24 hours following administration. *In Vitro* studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter). Pemetrexed total systemic clearance is 91.8 ml/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90 ml/min). Between patient variability in clearance is moderate at 19.3 %. Pemetrexed total systemic exposure (AUC) and maximum plasma concentration increase proportionally with dose. The pharmacokinetics of pemetrexed are consistent over multiple treatment cycles.

The pharmacokinetic properties of pemetrexed are not influenced by concurrently administered cisplatin. Oral folic acid and intramuscular vitamin B<sub>12</sub> supplementation do not affect the pharmacokinetics of pemetrexed.

#### Preclinical safety data

Administration of pemetrexed to pregnant mice resulted in decreased foetal viability, decreased foetal weight, incomplete ossification of some skeletal structures and cleft palate.

Administration of pemetrexed to male mice resulted in reproductive toxicity characterised by reduced fertility rates and testicular atrophy. In a study conducted in beagle dog by intravenous bolus injection for 9 months, testicular findings (degeneration/necrosis of the seminiferous epithelium) have been observed. This suggests that pemetrexed may impair male fertility. Female fertility was not investigated.

Pemetrexed was not mutagenic in either the *in vitro* chromosome aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be clastogenic in the *in vivo* micronucleus test in the mouse.

Studies to assess the carcinogenic potential of pemetrexed have not been conducted.

#### PHARMACEUTICAL PARTICULARS

##### List of excipients

Mannitol

Hydrochloric acid

Sodium hydroxide

##### Incompatibilities

Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer's Injection and Ringer's Injection. In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products.

##### Shelf life

3 years

**Reconstituted and Infusion Solutions:** When prepared as directed, reconstituted and infusion solutions of ALIMTA® contain no antimicrobial preservatives. Chemical and physical in-use stability of reconstituted and infusion solutions of pemetrexed were demonstrated for 24 hours at refrigerated temperature. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 to 8°C.

##### Special precautions for storage

**Unopened vial:** Store at controlled room temperature (below 25°C). For storage conditions of

ALRP INFORMATION	LLY INDIANAPOLIS PPD SITE
	PACKAGING SITE: ___INDY DRY <u>X</u> _PDAP      ___OTHER  OTHER REGULATED ITEMS: N/A

DIE ID	TEMPLATE NO: L-0180A FLAT DIMENSIONS: 10" x 22" FOLDED DIMENSIONS: 1.25" x 2"
--------	---

GRAPHICS	COLORS: BLACK      F/B
	CREATED BY: SKC      DATE: 17 Aug 2018
	ITEM CODE & VERSION NO: PA000IPRI02_C1
	SUPERSEDES: PA000IPRI01
	NON HR BARCODE: Code 128: 0003180902